Status:
COMPLETED
Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer
Lead Sponsor:
University of Michigan Rogel Cancer Center
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
We are trying to develop better ways to detect when cancer therapies are working.
Eligibility Criteria
Inclusion
- Females at least 18 years of age 2 Diagnosis of metastatic breast cancer 3.ECOG Score of 0-2 4.Treating oncologist has decided to initiate any new systemic therapy with emphasis on recruiting patients commencing a taxane-based regimen. Taxine-based therapy may be docetaxel or paclitaxel, and it can be given on any schedule,including weekly or every 3 weeks. Other treatment can include non-taxane chemotherapy or trastuzumab-with or without other therapy.
- Patient is willing to return for one or more additional \~18 mL blood draw (s) at 24-48-, and /or 72 hours and \~3-4 weeks after the initiation of therapy.At a minimum, patients must donate blood at baseline, one intermediate interval (24, 48, 72 hr) and at \~3-4 weeks 6.Signed Informed Consent Form
- \-
Exclusion
- Patient is unable and unwilling to provide a blood specimen at a minimum of one of the intermediate blood draw time points at 24, 48, or 72 hours -
Key Trial Info
Start Date :
April 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT00156273
Start Date
April 1 2005
End Date
October 1 2008
Last Update
July 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Cancer Center
Ann Arbor, Michigan, United States, 48109